# EDGAR Filing Document

**Accession Number:** 0001863362
**File Stem:** 0001213900-26-028339
**Filing Date:** 2026-3
**Character Count:** 3207
**Document Hash:** 2be58e1e02aa3d70e8ae7fc856eb8242
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-028339.hdr.sgml**: 20260316

**ACCESSION NUMBER**: 0001213900-26-028339

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260316

**DATE AS OF CHANGE**: 20260316

**EFFECTIVENESS DATE**: 20260316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sofgen Pharma S.A.
- **CENTRAL INDEX KEY:** 0001863362
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** N4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40851
- **FILM NUMBER:** 26757321

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 9 RUE DE BITBOURG
- **CITY:** LUXEMBOURG
- **PROVINCE COUNTRY:** N4
- **BUSINESS PHONE:** 575-371-9280

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 9 RUE DE BITBOURG
- **CITY:** LUXEMBOURG
- **PROVINCE COUNTRY:** N4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Procaps Group, S.A.
- **DATE OF NAME CHANGE:** 20210520

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER<br> SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION<br> OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE<br> SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number <u>001-40851</u>

**Sofgen Pharma S.A.**

(Exact name of registrant as specified in its charter)

**9 rue de Bitbourg, L-1273**

**Luxembourg**

**Grand Duchy of Luxembourg**

**R.C.S. Luxembourg: B253360**

**Tel: +356 7995-6138**

(Address, including zip code, and telephone number, including area code, of registrant's<br> principal executive offices)

**Ordinary shares, nominal value $0.01 per share**

**Warrants, exercisable for one ordinary share at an exercise price of $11.50 per share**

(Title of each class of securities covered by this Form)

**None**

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or<br> 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date:

Ordinary shares, nominal value $0.01 per share: 80 holders

Warrants, exercisable for one ordinary share at an exercise price of $11.50 per share: 44 holders

Pursuant to the requirements of the Securities Exchange Act of 1934, Sofgen Pharma S.A. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Page 2 of 3

---

| | | |
|:---|:---|:---|
|  | SOFGEN PHARMA S.A. | SOFGEN PHARMA S.A. |
| Date: March 16, 2026 | By: | /s/ Melissa Angelini |
|  |  | Name: Melissa Angelini |
|  |  | Title: Interim Chief Executive Officer |

---

Page 3 of 3